Press Releases

pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months Feb 07, 2018 Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months Fiscal Q2 2018 Results Conference Call Scheduled for Today at 4:30 p.m.ET WATERTOWN, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development Read more
pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information Jan 24, 2018 Conference Call Scheduled for 4:30 p.m. ET on Wednesday, February 7th Read more
pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA Jan 08, 2018 Proven Durasert Technology Has to Date Received FDA Approval for Three of the Four Sustained Release Drug Products Approved for Back-of-the-Eye Diseases Read more
pSivida Granted Waiver by the FDA for New Drug Application Filing Fee Jan 04, 2018 WATERTOWN, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, today announced that the U.S. Food and Drug Administration (FDA) granted its request for a small business waiver of the Prescription Read more
pSivida to Present at the Annual Biotech Showcase Conference Jan 02, 2018 WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, announced today that Nancy Lurker , President and Chief Executive Officer, will present at the Annual Biotech Showcase conference on Read more
HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data Dec 14, 2017 Sustained Release Technology Well Tolerated and Provides Pain Reduction Read more
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution Nov 07, 2017 NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early January 2018 Conference Call and Webcast Today, November 7th , at 8:30 a.m. ET WATERTOWN, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. Read more
pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information Oct 18, 2017 Conference Call Scheduled for 8:30 a.m. ET on Tuesday, November 7th Read more
pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma Oct 10, 2017 Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds Read more
pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs Sep 26, 2017 WATERTOWN, Mass. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has signed an agreement with a major global pharmaceutical company to develop two glaucoma drugs with pSivida's proprietary Read more
pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 22, 2017 WATERTOWN, Mass. , Sept. 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2017 Read more
pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results Sep 11, 2017 Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis Conference Call and Webcast Today, September 11th , at 4:30 p.m. ET WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained Read more
pSivida to Present at Rodman & Renshaw Annual Global Investment Conference Sep 11, 2017 WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Nancy Lurker , President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Read more
pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th Sep 05, 2017 WATERTOWN, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, will report results for its fourth quarter and fiscal year ended June 30, 2017 on Monday, Read more
pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017 Aug 01, 2017 WATERTOWN, Mass. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases, today announced that Nancy Lurker , President and Chief Executive Officer, will present at the Read more
Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences Jul 18, 2017 WATERTOWN, Mass. , July 18, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that three abstracts supporting the Company's Durasert™ three-year treatment for posterior segment uveitis Read more
pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida's Revenue Generation Jul 10, 2017 WATERTOWN, Mass. , July 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences, Inc. Read more
pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson Jun 28, 2017 WATERTOWN, Mass. , June 28, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Kristine Peterson , a seasoned healthcare executive has been elected to the Company's Board of Read more
pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union Jun 22, 2017 WATERTOWN, Mass. , June 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market Read more
pSivida's Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study Jun 13, 2017 Highly Significant Difference Observed Between Durasert and Control Group in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 p.m.ET WATERTOWN, Mass. , June 13, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of Read more

pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months

Feb 07, 2018

pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information

Jan 24, 2018

pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA

Jan 08, 2018

pSivida Granted Waiver by the FDA for New Drug Application Filing Fee

Jan 04, 2018

pSivida to Present at the Annual Biotech Showcase Conference

Jan 02, 2018

HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

Dec 14, 2017